Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma.

Stéphanie Durand-PanteixJacques MonteilMagali SageArmand GarotMarie ClavelAmal SaidiJulien TorgueMichel Cogné Isabelle Quelven

Published in: British journal of cancer (2021)

These results show the efficacy of 212Pb-rituximab in a murine syngeneic lymphoma model, in terms of significant tumour regression and increased survival, thereby highlighting the potency of α-RIT for the treatment of NHL.

Keyphrases

diffuse large b cell lymphoma
heavy metals
aqueous solution
cancer therapy
stem cells
risk assessment
cell therapy
mesenchymal stem cells
nk cells
replacement therapy